BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Ovarian cancer AND MLH1, COCA2, 4292, ENSG00000076242, hMLH1, FCC2, HNPCC2, P40692, MGC5172, HNPCC
582 results:

  • 1. Clonal origin and genomic diversity in Lynch syndrome-associated endometrial cancer with multiple synchronous tumors: Identification of the pathogenicity of mlh1 p.L582H.
    Takahashi K; Yachida N; Tamura R; Adachi S; Kondo S; Abé T; Umezu H; Nyuzuki H; Okuda S; Nakaoka H; Yoshihara K
    Genes Chromosomes Cancer; 2024 Mar; 63(3):e23231. PubMed ID: 38459936
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. HER2-low and Overexpression in Mucinous ovarian cancer: Analysis of ASCO/CAP and ToGA Immunohistochemical Scoring.
    Han R; Madariaga A; Gonzalez-Ochoa E; Smith AC; Wang L; Lheureux S; Rouzbahman M
    Int J Gynecol Pathol; 2024 May; 43(3):275-283. PubMed ID: 38436360
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Direct letters to relatives at risk of hereditary cancer-study protocol for a multi-center randomized controlled trial of healthcare-assisted versus family-mediated risk disclosure at Swedish cancer genetics clinics (DIRECT-study).
    Hawranek C; Ehrencrona H; Öfverholm A; Hellquist BN; Rosén A
    Trials; 2023 Dec; 24(1):810. PubMed ID: 38105176
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Specific Pathology Features Enrich Selection of Endometrial Carcinomas for POLE Testing.
    Keyhanian K; Han L; Howitt BE; Longacre T
    Am J Surg Pathol; 2024 Mar; 48(3):292-301. PubMed ID: 38062789
    [TBL] [Abstract] [Full Text] [Related]  

  • 5.
    Carnevali IW; Cini G; Libera L; Sahnane N; Facchi S; Viel A; Sessa F; Tibiletti MG
    Genes (Basel); 2023 Nov; 14(11):. PubMed ID: 38003003
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Functional and phenotypic consequences of an unusual inversion in MSH2.
    Pelletier D; Rath A; Sabbaghian N; Pelmus M; Hudon C; Jacob K; Witowski L; Saskin A; Heinen CD; Foulkes WD
    Fam Cancer; 2024 Mar; 23(1):1-7. PubMed ID: 37957483
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Expression of EGFR, PD-L1, and the mismatch repair proteins before and following therapy in malignant serous effusions with metastatic high-grade serous tubo-ovarian carcinoma.
    Nikas IP; Park SY; Song MJ; Lee C; Ryu HS
    Diagn Cytopathol; 2024 Feb; 52(2):69-75. PubMed ID: 37937321
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Applicability of the FDA-approved Immunohistochemical Panel for Identification of MMRd Phenotype in Uterine Endometrioid Carcinoma.
    Adachi S; Kimata JI; Hanami K; Adachi K; Igarashi T; Liang SG; Ishida Y; Fujino T; Yamazaki K
    Appl Immunohistochem Mol Morphol; 2024 Jan; 32(1):24-31. PubMed ID: 37859432
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Molecular Classification of Endometrial Endometrioid Carcinoma With Microcystic Elongated and Fragmented Pattern.
    Ju B; Wu J; Sun L; Yang C; Yu H; Hao Q; Wang J; Zhang H
    Int J Gynecol Pathol; 2024 May; 43(3):233-241. PubMed ID: 37733028
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Muir-Torre syndrome and recent updates on screening guidelines: The link between colorectal tumors and sebaceous adenomas in unusual locations.
    Shaker N; Shaker N; Abid A; Shah S; Shakra RA; Sangueza OP
    J Surg Oncol; 2023 Dec; 128(8):1380-1384. PubMed ID: 37706607
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Clinicopathologic significance of mismatch repair protein expression in endometrioid endometrial cancer.
    Kim MK; So KA; Chun YK; Kim YH; Lim KT; Lee KH; Kim TJ
    Taiwan J Obstet Gynecol; 2023 Sep; 62(5):724-728. PubMed ID: 37679002
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Retrospective Cohort Study on the Limitations of Direct-to-Consumer Genetic Screening in Hereditary Breast and ovarian cancer.
    Desai NV; Barrows ED; Nielsen SM; Hatchell KE; Anderson MJ; Haverfield EV; Herrera B; Esplin ED; Lucassen A; Tung NM; Isaacs C
    JCO Precis Oncol; 2023 Aug; 7():e2200695. PubMed ID: 37535880
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Uncommon variants detected via hereditary cancer panel and suggestions for genetic counseling.
    Özdemir Z; Çevik E; Öksüzoğlu ÖBÇ; Doğan M; Ateş Ö; Esin E; Bilgetekin İ; Demirci U; Köseoğlu Ç; Topal A; Karadurmuş N; Erdem HB; Bahsi T
    Mutat Res; 2023; 827():111831. PubMed ID: 37453313
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Risk-reducing salpingo-oophorectomy among Chinese women at increased risk of breast and ovarian cancer.
    Feng Z; Zuo K; Ju X; Chen X; Yang W; Wen H; Yu L; Wu X
    J Ovarian Res; 2023 Jun; 16(1):125. PubMed ID: 37386498
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Undifferentiated component of dedifferentiated endometrial carcinoma presenting as a "small round cell" malignancy in a mediastinal lymph node, mimicking small cell carcinoma.
    Balikani L; Policarpio-Nicolas MLC
    Diagn Cytopathol; 2023 Aug; 51(8):519-524. PubMed ID: 37318779
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Clinicopathological and Survival Characteristics of Mismatch Repair Status and PD-1 Expression in Serous ovarian cancer.
    Olmez F; Oglak SC; Akgol S; Olmez OF; Bilici A; Akbayir O; Ozkose ZG; Can E; Unal O; Sirinoglu HA
    J Coll Physicians Surg Pak; 2023 Jun; 33(6):666-672. PubMed ID: 37300263
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Risk of Syndrome-Associated cancers Among First-Degree Relatives of Patients With Pancreatic Ductal Adenocarcinoma With Pathogenic or Likely Pathogenic Germline Variants.
    Chen X; Meyer MA; Kemppainen JL; Horibe M; Chandra S; Majumder S; Petersen GM; Rabe KG
    JAMA Oncol; 2023 Jul; 9(7):955-961. PubMed ID: 37200008
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. High-grade serous ovarian carcinoma with a sertoliform pattern associated with BRCA mutation: a clinicopathological and molecular analysis.
    Travaglino A; Santoro A; Arciuolo D; Raffone A; Scaglione G; D'Alessandris N; Valente M; Sfregola S; Fulgione C; Onori ME; Minucci A; Zannoni GF
    Virchows Arch; 2023 Dec; 483(6):879-883. PubMed ID: 37166561
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Mismatch repair-deficient glioma with spatially distinct IDH-mutant and IDH-wild type components arising in the setting of Lynch syndrome.
    Tan H; Nerison C; Stateler C; Bowden SG; Raslan AM; Ambady P; Barajas RF; Wood MD
    Cold Spring Harb Mol Case Stud; 2023 Apr; 9(2):. PubMed ID: 37076313
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. BRD4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumors.
    Fu Y; Yang B; Cui Y; Hu X; Li X; Lu F; Qin T; Zhang L; Hu Z; Guo E; Fan J; Xiao R; Li W; Qin X; Hu D; Peng W; Liu J; Wang B; Mills GB; Chen G; Sun C
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37072347
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 30.